Arbutus Biopharma, a Nasdaq-listed Canadian biopharmaceutical company, has appointed Lisa Caperelli as vice president of investor relations.
In this newly created position, Caperelli leads investor relations strategy and communications activities, and reports to CFO David Hastings.
Most recently, she served as associate vice president of investor relations at Harmony Biosciences, a US pharmaceutical company. Before that, she held IR, corporate communications and patient advocacy roles with several biotech companies including Marinus Pharmaceuticals, Advaxis, PolyMedix and Windtree Therapeutics.
‘We are excited to welcome Lisa to the management team as she brings a wealth of experience in running highly effective investor relations and communications programs in the life sciences industry,’ says Hastings in a press release.
‘We look forward to leveraging her expertise to communicate our differentiated approach for developing a combination regimen to provide a functional cure for people living with [hepatitis B] and our ongoing efforts related to our coronavirus discovery program.’
Caperelli adds in the statement: ‘I am excited to join the Arbutus team, which is experienced in the development of antivirals and passionate about developing therapies for chronic HBV infection and coronaviruses. I look forward to interacting with the investment community as we continue to advance our pipeline.’
